How Much Weight Can You Lose on Semaglutide & Tirzepatide? 2026 Data
The numbers are in — and they're remarkable. Semaglutide produces an average 14.9% body weight loss in 68 weeks (STEP 1 trial), while tirzepatide delivers 22.5% over 72 weeks (SURMOUNT-1 trial). But averages don't tell the full story. Your actual results depend on starting weight, dose, lifestyle factors, and consistency. This guide breaks down exactly what the data says — and what you can do to land in the top tier of outcomes.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. This article presents clinical trial data and evidence-based guidance for educational purposes. It is not a substitute for individualized medical advice.
Quick links: Semaglutide $99/mo, Tirzepatide $125/mo, Semaglutide vs tirzepatide comparison.
More on GLP-1 Weight Loss Results
Semaglutide vs Tirzepatide: Key Differences
Side-by-side comparison of mechanism, dosing, cost, and clinical outcomes.
First Month on Semaglutide or Tirzepatide
What to expect during your first 4 weeks on a GLP-1 medication.
Exercise Doubles GLP-1 Results
How structured exercise amplifies weight loss on semaglutide and tirzepatide.
GLP-1 Plateau Breakthrough Guide
Evidence-based strategies when your weight loss stalls on GLP-1 medications.
The Clinical Trial Numbers: What the Data Actually Shows
Two landmark trials define what we know about GLP-1 weight loss outcomes: STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide. Both were published in the New England Journal of Medicine and represent the gold standard for obesity pharmacotherapy evidence.
STEP 1 Trial — Semaglutide 2.4 mg Weekly
- Average body weight reduction: 14.9% at 68 weeks
- Average pounds lost: ~34 lbs (based on mean starting weight of ~232 lbs)
- Participants losing ≥5% body weight: 86.4%
- Participants losing ≥10%: 69.1%
- Participants losing ≥15%: 50.5%
- Participants losing ≥20%: 32.0%
- Study design: Randomized, double-blind, placebo-controlled; N=1,961
Source: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
SURMOUNT-1 Trial — Tirzepatide (5, 10, and 15 mg Weekly)
- Average body weight reduction at 15 mg: 22.5% at 72 weeks
- Average body weight reduction at 10 mg: 21.4%
- Average body weight reduction at 5 mg: 16.0%
- Participants losing ≥20% body weight (15 mg): 57.5%
- Participants losing ≥25% body weight (15 mg): 36.2%
- Study design: Randomized, double-blind, placebo-controlled; N=2,539
Source: Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
These numbers establish the ceiling of what's achievable under optimal conditions with consistent, fully titrated dosing. Real-world results are typically 60–80% of trial outcomes, but the gap narrows significantly with strong lifestyle habits and good clinical support — both of which Trimi's program is built around.
Month-by-Month Weight Loss Timeline
Weight loss on GLP-1 medications is not linear. It follows a predictable pattern driven by dose titration — slower at the start, fastest in the middle, then tapering toward a new set point. Understanding the timeline helps set realistic expectations and avoid discouragement during the slower phases.
See our detailed guide on what to expect in your first month on semaglutide or tirzepatide for a deep dive into the early-treatment experience.
Month 1 (Weeks 1–4)
Semaglutide (avg)
1–4 lbs (~0.5–2%)
Tirzepatide (avg)
2–5 lbs (~1–2.5%)
Starting dose is low (0.25 mg semaglutide / 2.5 mg tirzepatide) to minimize side effects. Appetite suppression begins but is mild. Focus on building injection routine and reducing processed food intake.
Month 2 (Weeks 5–8)
Semaglutide (avg)
4–8 lbs (~2–4%)
Tirzepatide (avg)
5–10 lbs (~2.5–5%)
First dose increase. Appetite suppression becomes more noticeable. Many patients report a dramatic reduction in food noise — the constant preoccupation with eating. Weight loss accelerates.
Month 3 (Weeks 9–12)
Semaglutide (avg)
6–12 lbs (~3–6%)
Tirzepatide (avg)
8–15 lbs (~4–7%)
Dose continues titrating upward. This is typically the fastest loss month for most patients. Cumulative loss from start often reaches the 5–10% range that delivers meaningful metabolic benefits.
Months 4–6
Semaglutide (avg)
10–20 lbs (~5–10%)
Tirzepatide (avg)
15–28 lbs (~7.5–14%)
Approaching or reaching maintenance dose. Loss rate begins to moderate slightly as the body adapts. Lifestyle factors — protein intake, exercise, sleep — become increasingly important at this stage.
Months 7–9
Semaglutide (avg)
15–28 lbs (~7.5–14%)
Tirzepatide (avg)
22–40 lbs (~11–20%)
Most patients are on their target dose. A weight loss plateau (stall of 4+ weeks) may appear here; this is normal and manageable. See our guide on breaking through a GLP-1 plateau.
Months 10–12
Semaglutide (avg)
20–35 lbs (~10–17%)
Tirzepatide (avg)
28–50 lbs (~14–25%)
Patients who have maintained consistent treatment are approaching clinical trial averages. Those who have optimized diet and exercise tend to be at the higher end. Year-one results often plateau here.
Months 13–18+
Semaglutide (avg)
25–40+ lbs (~12–20%+)
Tirzepatide (avg)
35–60+ lbs (~17–30%+)
Continued gradual loss toward individual weight set point. Some patients achieve results well above trial averages with strong lifestyle support. Maintenance planning becomes the priority.
Expected Results by Starting BMI
Clinical trial data stratified by BMI reveals an important pattern: percentage body weight loss is relatively consistent across BMI categories, but absolute pounds lost scales with starting weight. Eligibility thresholds also vary by BMI class.
Not sure if you qualify? Our BMI requirements for weight loss medications guide and GLP-1 candidacy checklist walk through the full eligibility criteria.
| Starting BMI | Example Starting Weight | Sema Avg Loss (14.9%) | Tirze Avg Loss (22.5%) | Notes |
|---|---|---|---|---|
| 27–29.9 (Overweight + comorbidity) | 185 lbs | ~28 lbs | ~42 lbs | Eligible with ≥1 weight-related comorbidity. Fewer absolute pounds but often near-normal BMI achievable. |
| 30–34.9 (Class I Obesity) | 215 lbs | ~32 lbs | ~48 lbs | Most common starting range. Majority reach BMI <30 with full course of treatment. |
| 35–39.9 (Class II Obesity) | 260 lbs | ~39 lbs | ~58 lbs | Strong responders in clinical trials. Tirzepatide frequently achieves BMI <30 from this range. |
| 40–44.9 (Class III Obesity) | 310 lbs | ~46 lbs | ~70 lbs | Highest absolute pound losses. Percentage loss consistent with other BMI classes. |
| ≥45 (Severe Obesity) | 370 lbs | ~55 lbs | ~83 lbs | May require extended treatment duration. Additional dose escalation strategies may apply. |
These projections use published trial mean percentage losses applied to example weights. Individual results vary. Patients who combine medication with high-protein diet and regular exercise consistently achieve outcomes at or above trial averages. For context on BMI-specific treatment eligibility, read our guide on GLP-1 at BMI 30.
Semaglutide vs Tirzepatide: Results Comparison
The most common question in weight loss pharmacotherapy today: which medication produces better results? Here is what the data shows — and what it means for choosing between them.
For a deeper look, see our full tirzepatide vs semaglutide 2026 comparison and the cost-effectiveness analysis.
Semaglutide
- Mechanism: GLP-1 receptor agonist (single agonism)
- Clinical trial loss: 14.9% at 68 weeks (STEP 1)
- Typical real-world loss: 10–18%
- Trimi price: $99/month
- Best for: Cost-conscious patients, those newer to GLP-1s, patients with more GI sensitivity
- 10+ year safety record in type 2 diabetes (as Ozempic)
Tirzepatide
- Mechanism: Dual GIP + GLP-1 receptor agonist
- Clinical trial loss: 22.5% at 72 weeks (SURMOUNT-1)
- Typical real-world loss: 15–25%
- Trimi price: $125/month
- Best for: Patients seeking maximum results, those who plateaued on semaglutide, patients with higher starting BMI
- Fastest-growing obesity medication by prescription volume in 2025–2026
Bottom line on choosing between them
If maximum weight loss is your primary goal and you can tolerate either medication, tirzepatide's dual mechanism gives it a consistent edge of 5–8 percentage points in trial data. At only $26 more per month through Trimi, the incremental cost-per-pound-lost often favors tirzepatide for higher-BMI patients. However, semaglutide's longer safety record and lower starting cost make it the preferred first choice for many providers, especially patients newer to injectable medications. Many Trimi patients start with semaglutide and switch to tirzepatide after establishing their tolerance.
Real-World Results vs Clinical Trial Data: The Gap Explained
Clinical trials consistently outperform real-world outcomes by 20–40%. Understanding why helps you close the gap. The explanation is not that the medication "doesn't work as well" outside trials — it's that trial conditions optimize every factor that influences results.
Why Trial Results Are Higher
- Participants receive structured dietary counseling throughout the trial
- Exercise guidance and monitoring is provided
- 100% dose titration compliance (no missed doses)
- Frequent provider check-ins catch and correct problems early
- Trial participants are highly motivated and screened for adherence
- Exclusion of participants who would reduce the average (those who drop out in real life)
- Controlled food environment reduces ultra-processed food exposure
Common Real-World Gaps
- Staying at a lower dose longer than necessary to avoid side effects
- Inconsistent injection timing or occasional missed doses
- Insufficient protein intake (under 100g/day) leads to muscle loss vs fat loss
- Inadequate hydration worsens nausea and slows results
- No structured exercise — physical activity multiplies outcomes
- Poor sleep (under 7 hours) disrupts appetite hormones and slows progress
- Continuing to eat highly palatable ultra-processed foods despite appetite suppression
Real-world studies in 2023–2025 consistently report average losses of 10–14% on semaglutide and 14–19% on tirzepatide — meaningful results by any clinical standard, even if below trial peaks. Patients who work with a structured program like Trimi and actively address the common gaps above routinely achieve outcomes at or above clinical trial averages.
Factors That Determine Your Individual Results
Weight loss on GLP-1 medications is not one-size-fits-all. These are the primary variables that shift individual outcomes across a wide range — and what you can do about each one.
Dose Titration
High ImpactReaching and maintaining your target dose (2.4 mg semaglutide or 10–15 mg tirzepatide) is the single most important modifiable factor. Patients who stay at subtherapeutic doses to avoid side effects miss significant outcome potential. Work with your Trimi provider to titrate at the pace your body tolerates — not the fastest possible pace.
Dietary Protein Intake
High ImpactGLP-1 medications suppress appetite but don't distinguish between fat and muscle loss. Without adequate protein (1.2–1.6g/kg body weight daily), significant lean mass loss occurs — which slows metabolism and worsens long-term results. Prioritize high-protein foods at every meal. Explore our guide on the best protein shakes for semaglutide patients.
Physical Activity
High ImpactHead-to-head data shows that patients who combine GLP-1 medications with structured exercise lose 20–40% more weight than those who rely on medication alone. Resistance training is especially important for preserving lean muscle mass during caloric restriction. Even 150 minutes of moderate activity per week produces significant outcome improvements.
Adherence and Consistency
High ImpactSkipping doses, extended breaks, or self-discontinuing and restarting disrupts the steady-state pharmacology that drives results. A single missed weekly dose loses approximately 1/4 of that week's therapeutic effect. Set a recurring injection day and treat it as non-negotiable.
Sleep Quality
Moderate–High ImpactInsufficient sleep (under 7 hours) elevates ghrelin (hunger hormone) and cortisol, actively working against the appetite-suppressing effects of GLP-1 medications. Patients who consistently sleep 7–9 hours lose measurably more weight than those who sleep less, even on the same medication and dose.
Baseline Metabolic Health
Moderate ImpactInsulin resistance, thyroid dysfunction, PCOS, and other metabolic conditions can slow GLP-1 weight loss. Your Trimi provider can identify and address these factors. Notably, GLP-1 medications often improve insulin resistance over time, which can accelerate later weight loss even if early results are slower.
Genetics and Response Variability
Moderate ImpactA small percentage of patients (roughly 5–10%) are metabolic non-responders to specific GLP-1 agents. If you lose less than 5% body weight after 12 weeks at a therapeutic dose, this warrants a discussion with your provider about switching medications or adding complementary treatments.
How to Maximize Your Weight Loss Results
Patients who consistently apply the following strategies achieve outcomes in the top quartile of real-world data — and often at or above clinical trial averages. These aren't optional enhancements; they're the difference between average and exceptional outcomes.
1. Protein: The Non-Negotiable Macro
GLP-1 medications create a calorie deficit by reducing appetite. Without sufficient protein, that deficit pulls from muscle tissue rather than fat — exactly the opposite of what you want. High protein intake (1.2–1.6g per kg of body weight) preserves lean mass, keeps metabolism elevated, and reduces hunger independently of the medication.
Practical targets: 30g protein at breakfast, 30–40g at lunch, 30–40g at dinner. Greek yogurt, eggs, cottage cheese, chicken, fish, and whey protein shakes are efficient options. See our guide to the best protein shakes for semaglutide for convenient options that don't feel like medicine.
Protein target by weight:
- 150 lbs (68 kg): 82–109g protein/day
- 200 lbs (91 kg): 109–145g protein/day
- 250 lbs (113 kg): 136–181g protein/day
- 300 lbs (136 kg): 163–218g protein/day
2. Exercise: The Result Multiplier
Studies show that GLP-1 patients who exercise lose 20–40% more weight than those who rely on medication alone — a massive amplification for a modest time investment. Resistance training (2–3 sessions per week) is the most effective modality for preserving muscle and accelerating fat loss. Cardio (150+ minutes/week) amplifies the metabolic and cardiovascular benefits.
Starting exercise is difficult when you're overweight or de-conditioned. Our beginner exercise plan for semaglutide patients starts with just 20-minute walks and progresses safely over 12 weeks.
For more data on the exercise-GLP1 synergy, read how exercise doubles GLP-1 results.
3. Hydration: The Underrated Accelerator
Dehydration is the most common and most underappreciated obstacle to GLP-1 results. Many patients on semaglutide or tirzepatide eat and drink significantly less than they used to — often including fluids — resulting in chronic mild dehydration that impairs fat metabolism, worsens side effects, and reduces energy for exercise.
Target intake: 2.5–3.5 liters (85–118 oz) of water daily. Electrolyte supplementation — particularly sodium, potassium, and magnesium — helps prevent the "GLP-1 fatigue" many patients experience in early treatment. Read our guide on electrolytes for GLP-1 dehydration for evidence-based supplementation recommendations.
4. Injection Technique and Timing
Optimal absorption requires proper injection technique. Inject into subcutaneous fat in the abdomen, thigh, or upper arm — rotating sites weekly to prevent lipodystrophy. Inject on the same day each week, at the same time of day, to maintain consistent plasma levels. See our guide on best injection sites for GLP-1 medications for technique details. For timing considerations, read the best time of day to inject your GLP-1.
Setting Realistic Expectations: What Success Actually Looks Like
Unrealistic expectations are the primary driver of early discontinuation — the most common reason GLP-1 treatment fails. Here's what success truly looks like at different stages, calibrated to evidence rather than marketing.
Week 1–2: Almost Nothing on the Scale
Starting doses are designed to minimize side effects, not maximize weight loss. Losing 0–2 lbs in the first two weeks is completely normal and does not predict long-term outcomes. Many patients notice appetite changes before any scale movement.
Month 1–2: 1–4 lbs — This Is Working
Early slow loss frustrates many patients who expect dramatic results immediately. But the metabolic foundation is being laid. The medication is sensitizing receptors and establishing steady-state levels. Patients who stick through months 1–2 almost universally experience acceleration in month 3.
The "4-Week Plateau": Expect and Plan for It
Between 60–70% of GLP-1 patients experience a stall of 3–6 weeks, typically around months 4–6. This is a normal metabolic adaptation response, not a sign of failure. Most plateaus break within 2–4 weeks with minor adjustments to protein intake, calorie composition, or exercise. Read our GLP-1 plateau breakthrough guide before you reach this phase so you know exactly what to do.
The Final 20%: Slower but Achievable
The last portion of weight loss toward your goal is always the slowest. As body weight decreases, energy expenditure drops, making further deficit increasingly difficult. This is normal physiology, not medication failure. Dose optimization and exercise intensity adjustments often reinvigorate progress at this stage.
Success Is More Than the Scale
Even 5–10% body weight loss produces clinically significant reductions in blood pressure, HbA1c, triglycerides, sleep apnea severity, and joint pain. Patients who focus solely on scale outcomes miss the substantial health benefits accumulating at every step. A 200 lb patient who loses 20 lbs has meaningfully reduced cardiovascular disease risk, even if their goal was 50 lbs.
The Trimi approach to realistic expectations
Every Trimi patient receives a personalized outcome projection based on their starting weight, BMI, medical history, and lifestyle factors — not a generic promise based on trial averages. Your Trimi provider sets checkpoints at 4, 8, and 12 weeks to assess response and adjust the plan before problems compound. This proactive approach is why Trimi patients consistently achieve results in the top quartile of real-world data.
Frequently Asked Questions
How much weight can you lose on semaglutide?
In the STEP 1 clinical trial, participants taking 2.4 mg weekly semaglutide lost an average of 14.9% of their body weight over 68 weeks — roughly 15 lbs for every 100 lbs of starting weight. Real-world outcomes range from 10% to 20% depending on adherence, diet, exercise, and individual metabolic response. Starting Trimi's semaglutide program at $99/month gives you access to ongoing clinical support to help you reach the higher end of that range.
How much weight can you lose on tirzepatide?
In the SURMOUNT-1 clinical trial, participants taking 15 mg weekly tirzepatide lost an average of 22.5% of their body weight over 72 weeks. The highest-dose arm saw 20.9% mean loss, with many participants losing 25% or more. Tirzepatide's dual GIP and GLP-1 mechanism generally produces greater weight loss than semaglutide alone. Trimi offers tirzepatide starting at $125/month.
How soon do you start losing weight on semaglutide or tirzepatide?
Most patients notice measurable weight loss within the first 4 weeks of treatment. The first month typically produces 2–4 lbs of loss as appetite suppression begins. Month 2–3 often brings the most dramatic results — 1–2 lbs per week — as the dose increases during titration. Weight loss continues at a slower but steady pace through months 4–12 and beyond.
Does starting BMI affect how much weight you lose?
Yes, starting BMI significantly affects absolute pounds lost, though percentage body weight loss is more consistent across BMI groups. Patients with a starting BMI of 40 or higher tend to lose the most pounds in absolute terms because they have more weight to lose. However, percentage losses are comparable — roughly 14–23% across BMI categories in clinical trials. Patients closer to their goal weight (BMI 27–30) may see the same percentage loss but a smaller number on the scale.
What is the difference in weight loss between semaglutide and tirzepatide?
Head-to-head and comparative data consistently show tirzepatide produces about 5–8 percentage points more weight loss than semaglutide. SURMOUNT-1 tirzepatide: 22.5% average loss. STEP 1 semaglutide: 14.9% average loss. For a 250 lb person, that difference translates to roughly 12–18 additional pounds. Tirzepatide's dual GIP plus GLP-1 agonism explains the advantage.
Why is my weight loss slower than the clinical trial averages?
Clinical trials use optimal conditions including structured diet counseling, close monitoring, and strict adherence protocols. Real-world results average 60–80% of trial outcomes. Common reasons for slower-than-expected results include inadequate protein intake (under 100g/day), not titrating to the full dose, skipping doses, minimal physical activity, stress-related cortisol elevation, and poor sleep. Working with your Trimi provider to address these factors can meaningfully improve your trajectory.
Will I regain weight if I stop semaglutide or tirzepatide?
Yes, most patients regain significant weight after stopping GLP-1 medications without a maintenance strategy. The STEP 4 trial found participants regained approximately two-thirds of lost weight within 52 weeks of stopping semaglutide. This is because GLP-1 medications work by modulating appetite hormones that reset when the drug is discontinued. Trimi's maintenance dosing program helps patients sustain results at lower monthly costs.
See What You Could Lose
Based on the clinical data: a 200 lb patient starting semaglutide today could weigh 170 lbs by spring 2027. Starting tirzepatide, they could weigh 155 lbs. Both outcomes are well-supported by trial data — and available through Trimi for $99 and $125 per month respectively.
Sources and References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 (STEP 1 trial)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 (SURMOUNT-1 trial)
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150.
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 4). Diabetes Obes Metab. 2022;24(8):1553-1564. (Regain after stopping)
- Tchang BG, Aras M, Kumar RB, Aronne LJ. Pharmacologic Treatment of Overweight and Obesity in Adults. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2021.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
- American Diabetes Association. Standards of Care in Diabetes — 2026. Diabetes Care. 2026;49(Supplement 1).
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Weight loss results vary significantly between individuals. The clinical trial averages cited (STEP 1: 14.9%, SURMOUNT-1: 22.5%) represent population means under controlled conditions and do not guarantee individual outcomes. GLP-1 receptor agonist medications require a prescription from a licensed healthcare provider and are not appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and active pancreatitis. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
More on GLP-1 Weight Loss
Semaglutide vs Tirzepatide: 2026 Key Differences
Complete head-to-head comparison of mechanism, efficacy, side effects, and cost.
How Long Does Semaglutide Take to Work?
Week-by-week breakdown of when semaglutide effects kick in.
GLP-1 Plateau Breakthrough
Proven strategies to break through weight loss stalls on GLP-1 medications.
Exercise Doubles GLP-1 Results
How combining exercise with GLP-1 medication amplifies fat loss outcomes.